ATE280579T1 - Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum - Google Patents

Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum

Info

Publication number
ATE280579T1
ATE280579T1 AT00959422T AT00959422T ATE280579T1 AT E280579 T1 ATE280579 T1 AT E280579T1 AT 00959422 T AT00959422 T AT 00959422T AT 00959422 T AT00959422 T AT 00959422T AT E280579 T1 ATE280579 T1 AT E280579T1
Authority
AT
Austria
Prior art keywords
methadone
alcohol consumption
partial
heroin
opioid antagonist
Prior art date
Application number
AT00959422T
Other languages
English (en)
Inventor
Thomas R Tice
Jay K Staas
Teresa M Ferrell
Peter Markland
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Application granted granted Critical
Publication of ATE280579T1 publication Critical patent/ATE280579T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
AT00959422T 1999-08-27 2000-08-25 Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum ATE280579T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15111299P 1999-08-27 1999-08-27
PCT/US2000/023390 WO2001015699A1 (en) 1999-08-27 2000-08-25 Injectable buprenorphine microparticle compositions and their use

Publications (1)

Publication Number Publication Date
ATE280579T1 true ATE280579T1 (de) 2004-11-15

Family

ID=22537367

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959422T ATE280579T1 (de) 1999-08-27 2000-08-25 Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum

Country Status (24)

Country Link
US (2) US6495155B1 (de)
EP (1) EP1212061B1 (de)
JP (1) JP4913298B2 (de)
KR (1) KR100730440B1 (de)
CN (2) CN100387228C (de)
AT (1) ATE280579T1 (de)
AU (1) AU765496C (de)
BR (1) BR0013650A (de)
CA (1) CA2382577C (de)
CY (1) CY1106043T1 (de)
CZ (1) CZ2002728A3 (de)
DE (1) DE60015370T2 (de)
EA (1) EA009080B1 (de)
ES (1) ES2230154T3 (de)
HK (1) HK1046858B (de)
HU (1) HUP0203613A3 (de)
IL (2) IL148343A0 (de)
MX (1) MXPA02002105A (de)
NO (2) NO322650B1 (de)
NZ (1) NZ517997A (de)
PL (1) PL198334B1 (de)
PT (1) PT1212061E (de)
RO (1) RO121631B1 (de)
WO (1) WO2001015699A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100387228C (zh) * 1999-08-27 2008-05-14 布鲁克伍德药品公司 可注射的美沙酮、部分类鸦片激动剂或类鸦片拮抗剂微粒组合物及其用途
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
BR0210722A (pt) * 2001-06-29 2004-07-20 Medgraft Microtech Inc Implantes injetáveis biodegradáveis e métodos relacionados de produção e uso
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
ATE376832T1 (de) 2001-07-06 2007-11-15 Penwest Pharmaceuticals Co Verzögert freisetzende formulierungen von oxymorphon
CN1610551A (zh) 2001-07-06 2005-04-27 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的肠胃外给药
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
WO2004078178A1 (en) * 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
FR2869801B1 (fr) * 2004-05-05 2008-09-12 Ethypharm Sa Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc)
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
WO2006012667A1 (en) * 2004-08-04 2006-02-09 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject.
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
WO2008106571A2 (en) 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
CA2699172C (en) 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
ES2718612T3 (es) * 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
CA2738197C (en) 2008-09-24 2016-01-05 Evonik Roehm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
KR101528957B1 (ko) 2008-09-24 2015-06-17 에보니크 룀 게엠베하 에탄올의 영향에 대하여 내성을 갖는 ｐｈ-의존성 조절 방출 제약학적 오피오이드 조성물
US20100268191A1 (en) * 2009-04-21 2010-10-21 Medtronic Vascular, Inc. Drug Delivery Catheter using Frangible Microcapsules and Delivery Method
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
CA3120681A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN102836131A (zh) * 2012-09-28 2012-12-26 山东大学 丁丙诺啡皮下注射用缓释微球制剂及其制备方法
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
JP6135292B2 (ja) * 2013-05-10 2017-05-31 ニプロ株式会社 マイクロカプセル製剤の製造方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
DK3215223T3 (da) 2014-11-07 2020-08-03 Indivior Uk Ltd Buprenorphindoseringsskemaer
WO2017147285A1 (en) 2016-02-23 2017-08-31 Biodelivery Sciences International, Inc. Sustained release buprenorphine microspheres (srbm) and methods of use thereof
KR102244500B1 (ko) 2016-09-13 2021-04-26 에일러 파마슈티컬스 아이엔씨. 서방형 부프레노르핀 제제
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CA3150767A1 (en) * 2019-08-12 2021-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions comprising a combination of opioid antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0471036B2 (de) 1989-05-04 2004-06-23 Southern Research Institute Einkapselungsverfahren
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5716631A (en) 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
CN100387228C (zh) * 1999-08-27 2008-05-14 布鲁克伍德药品公司 可注射的美沙酮、部分类鸦片激动剂或类鸦片拮抗剂微粒组合物及其用途

Also Published As

Publication number Publication date
EA200200295A1 (ru) 2002-08-29
HK1046858B (zh) 2005-03-24
KR100730440B1 (ko) 2007-06-19
IL148343A (en) 2008-03-20
JP4913298B2 (ja) 2012-04-11
NO20020924D0 (no) 2002-02-26
WO2001015699A1 (en) 2001-03-08
CA2382577C (en) 2008-01-22
AU765496C (en) 2005-08-25
EP1212061A1 (de) 2002-06-12
ES2230154T3 (es) 2005-05-01
US7473431B2 (en) 2009-01-06
JP2003508439A (ja) 2003-03-04
CN1382051A (zh) 2002-11-27
EP1212061B1 (de) 2004-10-27
PL198334B1 (pl) 2008-06-30
MXPA02002105A (es) 2003-12-11
CN1788721A (zh) 2006-06-21
EA009080B1 (ru) 2007-10-26
CA2382577A1 (en) 2001-03-08
CN1248689C (zh) 2006-04-05
DE60015370T2 (de) 2006-03-09
PT1212061E (pt) 2005-01-31
AU7075100A (en) 2001-03-26
KR20020053057A (ko) 2002-07-04
CY1106043T1 (el) 2011-04-06
HK1046858A1 (en) 2003-01-30
NO322650B1 (no) 2006-11-13
US20030152638A1 (en) 2003-08-14
NZ517997A (en) 2002-11-26
US6495155B1 (en) 2002-12-17
IL148343A0 (en) 2002-09-12
PL354977A1 (en) 2004-03-22
CN100387228C (zh) 2008-05-14
AU765496B2 (en) 2003-09-18
NO20063239L (no) 2002-04-03
NO20020924L (no) 2002-04-03
DE60015370D1 (de) 2004-12-02
RO121631B1 (ro) 2008-01-30
HUP0203613A3 (en) 2005-01-28
BR0013650A (pt) 2002-05-07
CZ2002728A3 (cs) 2002-08-14
HUP0203613A2 (hu) 2003-02-28

Similar Documents

Publication Publication Date Title
ATE280579T1 (de) Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
ATE262906T1 (de) Injizierbare naltrexon mikrosphären zusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
ATE244558T1 (de) Trockene formbare arzneistoffformulierung
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
EP1555023A3 (de) Injizierbare Buprenorphin-Mikropartikelformulierung und ihre Verwendung
ATE287265T1 (de) Verwendung von schwachen opioiden und gemischten opioidagonisten / -antagonisten zur therapie der harninkontinenz
Briggs et al. Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats
Tseng et al. Spinal δ2 but not δ1 opioid receptors are involved in intracereboventricular β-endorphin-induced antinociception in the mouse
AU9266698A (en) Acidic addition salts of morphine alkaloids and the application thereof
OELTGEN Characterization and utilization of opiate-like hibernation factors(Report, 15 Jul. 1992- 15 Dec. 1993)
Campi et al. ZT 52656A: EEG spectral analysis in freely-moving rats
李明霞 et al. PHARMACOLOGICAL STUDY OF AN IRREVERSIBLE PARTIAL AGONIST OF OPIATE RECEPTORS, A-α-CAO
Paquette Kappa-opioid induced regulation of mu-opioid mediated effects on EEG power spectra and behavior in rats.
AUPS010302A0 (en) Subcutaneous implant or injection combining opiate agonists and antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1212061

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee